Micropore particle technology

Ace Vision Group Appoints Cristos Ifantides M.D., MBA as Director, Clinical Applications Development

Retrieved on: 
Thursday, February 23, 2023
Aurora, Wills Eye Hospital, School, Sue, University, University of Colorado School of Medicine, Eye, MBA, National Institute for Health and Care Research, Biological engineering, VESA, Drug development, 3D, Research, AVG, Patient, Mount Sinai Hospital, Mount Sinai Hospital (Manhattan), Cataract, Laser, Surgeon, DPT, Health, Micropore particle technology, Presbyopia, College of Engineering (KNUST), Education, LSM, Medical device, Nursing, Hospital, Ophthalmology

BOSTON, Feb. 23, 2023 /PRNewswire/ -- Ace Vision Group, Inc, (AVG) an emerging ophthalmic device company focused on bringing innovative touchless lasers to patients suffering from age-related vision loss and eye diseases caused by ocular rigidity, announced the appointment of Cristos Ifantides, M.D., MBA as Director, Clinical Applications Development effective immediately.

Key Points: 
  • BOSTON, Feb. 23, 2023 /PRNewswire/ -- Ace Vision Group, Inc, (AVG) an emerging ophthalmic device company focused on bringing innovative touchless lasers to patients suffering from age-related vision loss and eye diseases caused by ocular rigidity, announced the appointment of Cristos Ifantides, M.D., MBA as Director, Clinical Applications Development effective immediately.
  • In his new role as Director, Clinical Applications Development, Dr. Ifantides will lead the education and clinical adoption efforts of AVG's forthcoming presbyopia technology platform.
  • Ifantides will spearhead efforts to continue development of the VESA® digital diagnostics artificial intelligence clinical platform.
  • VESA also has broader applications in virtual clinical simulations which could improve technology assisted research validation and test the efficacy of therapeutic interventions in virtual clinical settings.

MicroPort CRM Receives Approval in Japan for Alizea Bluetooth Pacemaker

Retrieved on: 
Monday, January 17, 2022
Patient, Micropore particle technology, Arrhythmia, MicroPort, Travel, ECG, Health, CRM, Cardiology, VP, Heart failure, Multimedia, Medical device

CLAMART, France, Jan. 16,2022 /PRNewswire/ -- MicroPort CRM, a pioneering company in the field of Cardiac Rhythm Management, headquartered in France, recently received PMDA Japanese regulation agency approval for its latest range of implantable pacemakers, Alizea.

Key Points: 
  • CLAMART, France, Jan. 16,2022 /PRNewswire/ -- MicroPort CRM, a pioneering company in the field of Cardiac Rhythm Management, headquartered in France, recently received PMDA Japanese regulation agency approval for its latest range of implantable pacemakers, Alizea.
  • The devices are equipped with Bluetooth technology for streamlined remote monitoring when paired with MicroPort CRM's SmartView Connect home monitor, already approved in Japan.
  • Benot Clinchamps, President of MicroPort CRM, noted, "We successfully launched Alizea in Europe in June 2021, and Japan is the second region to benefit from its advanced technological functions.
  • MicroPort CRM is a pioneering company in the field of Cardiac Rhythm Management (CRM), and a subsidiary of MicroPort Scientific Corporation (stock code: 00853.HK), with world headquarters in Clamart, near Paris, France.